Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 6/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19122314 | 0.87 | KDM4E (0.56) | GPBAR1FFAR1KDM4ETSHRGPR88 | |
| SCHEMBL12696830 | 0.86 | FFAR1 (0.50) | GPBAR1FFAR1KDM4ETSHRSCN4A | |
| SCHEMBL14846857 | 0.85 | SCN4A (0.46) | KDM4ETSHRSCN4A | |
| SCHEMBL12094272 | 0.85 | SCN4A (0.46) | KDM4ETSHRSCN4A | |
| SCHEMBL19191664 | 0.85 | SCN4A (0.46) | KDM4ETSHRSCN4A | |
| SCHEMBL17138170 | 0.84 | GPBAR1 (0.60) | GPBAR1FFAR1KDM4ETSHRTLR8 | |
| SCHEMBL4280414 | 0.83 | TP53 (0.56) | KDM4ETSHR | |
| SCHEMBL146850 | 0.83 | TP53 (0.56) | KDM4ETSHR | |
| SCHEMBL7640732 | 0.83 | TP53 (0.56) | KDM4ETSHR | |
| SCHEMBL12094233 | 0.82 | SCN4A (0.43) | KDM4ETSHRSCN4ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673908-B1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-2508185-A1 | ANTI-TUMOR EFFECT POTENTIATOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2295414-B1 | URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| WO-2011065541-A1 | ANTI-TUMOR EFFECT POTENTIATOR | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011065545-A1 | 5-FLUOROURACIL COMPOUND HAVING dUTPase-INHIBITING ACTIVITY OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009147843-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | CCNT1, CCNA1, UPP1 | GPBAR1 2766/4885FFAR1 2926/4885KDM4E 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.